Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (296)	8/27/2002 3:03:08 PM
From: scaram(o)uche	Respond to of 598

>> He expects that Tularik will double the number of drugs it has in clinical trials from three to six over the next 12 months. << So Reddoch is still looking at three INDs within the next year.

To: tuck who wrote (296)	8/27/2002 4:21:33 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 598

Instead, Tularik is conducting a 750-patient clinical test at cancer centers all over the world. Normally, the company would not see any results until all patients had been followed for the entire length of the trial, but Tularik will take a look at a small percentage of these patients while the clinical trials are still ongoing in order to make sure that there are no unexpected problems with the drug's safety or efficacy. The trial will seek to prove that patients given T67 survive longer than those who are not. My read on this is that TLRK will have an opportunity to pull the plug on the trials if the early indications don't look good, and the early glimpses should give them some idea of efficacy as well as safety. Given the preponderance of HCC cases in Asia, they may be able to conduct Asian trials at significantly lower cost. The other consideration is that they are working on a major unmet need, which could help expedite the review and approval process. Beyond that, I hope Banc of America's Reddoch is right about the company getting three more candidates into clinical trials within the next 12 months. B of A's last call on TLRK was so far off-target that you have to wonder what they were trying to hit.